Source - LSE Regulatory
RNS Number : 7784V
Deltex Medical Group PLC
10 April 2019
 

10 April 2019

 

 

Deltex Medical Group plc

("Deltex Medical", "Deltex" or "the Company")

 

 

Notice of Annual Results

 

 

Deltex Medical Group plc (AIM: DEMG), the global leader in Oesophageal Doppler Monitoring ("ODM"), will be announcing its Final Results for the year ended 31 December 2018 on Thursday 25 April 2019.

Management will be hosting a presentation for analysts on the day of results at 10:00 a.m. at the offices of Arden Partners plc, 125 Old Broad Street, London, EC2N 1AR.

Analysts who wish to attend should register their interest with Sarah-Jane Woodcock contactable at ir@arden-partners.com or 020 7614 5939.

 

Deltex Medical Group plc                            

01243 774 837

investorinfo@Deltexmedical.com

Nigel Keen, Chairman                


Andy Mears, Chief Executive   


Jonathan Shaw, Group Finance Director




Nominated Adviser & Broker


Arden Partners plc

020 7614 5900

 

Ciaran Walsh

Dan Gee-Summons




Joint Broker


Turner Pope Investments (TPI) Ltd

0203 621 4120

info@turnerpope.com

Andy Thacker


 

Notes for Editors

Deltex Medical manufactures and markets haemodynamic monitoring technologies. Deltex Medical's proprietary oesophageal doppler monitoring ("ODM") (TrueVue Doppler) is the only technology to measure blood flow in the central circulation in real time. Minimally invasive, easy to set-up and quick to focus, the technology generates a low-frequency ultrasound signal which is highly sensitive to changes in flow and measures such changes in 'real time'. Deltex Medical has been the only company in the enhanced haemodynamic space to build a robust and credible evidence base proving the clinical and economic benefits of its core technology, TrueVue Doppler, which has been demonstrated in a wide range of clinical trials to reduce complications suffered by patients after surgery and save hospitals the costs of treating those complications.

 

Deltex Medical's TrueVue System on the CardioQ-ODM+ monitor platform now provides clinicians with two further advanced haemodynamic monitoring technologies. TrueVue Impedance is an entirely non-invasive monitoring technology which creates an electrical field across the chest and measures the disruption to this field when the heart pumps blood. TrueVue PressureWave uses the peripheral blood pressure signal analysis to give doctors information on changes in the circulation and is particularly suited to monitoring lower risk or haemodynamically stable patients.

 

Group goal

Haemodynamic management is now becoming widely accepted as an important part of the anaesthesia protocol for high risk surgical patients. Consequently, the Group's focus is on maximising value from the opportunities presented, as enhanced haemodynamic management is adopted into routine clinical practice around the world. The Group aims to provide clinicians with a single platform - a 'haemodynamic workstation' - which offers them a range of technologies from simple to sophisticated to be deployed according to the patient's condition as well as the skill and expertise of the user. Doing this will enable the Group to partner healthcare providers to support modern haemodynamic management across the whole hospital.

 

The Group is currently in the implementation phase of achieving this goal in a number of territories worldwide, operating directly in the UK and the USA - and through distribution arrangements in approximately 40 other countries.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NORCKKDKKBKDFQD
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.